Table 2.
Concordance for detection of major somatic mutations in tumor tissue and serum samples from patients with non‐small cell lung carcinoma using next‐generation sequencing (NGS) and digital PCR
| Mutation | Case no. | NGS (% of variant reads) | Digital PCR (copy number) | ||
|---|---|---|---|---|---|
| Tumor | Serum | Tumor | Serum | ||
| EGFR L858R | 55 | 16.3 | n.d. | 2520 | n.d. |
| 66 | 45.8 | n.d. | 4880 | n.d. | |
| 71 | 24.2 | n.d. | 2280 | n.d. | |
| 74 | 33.4 | n.d. | 2240 | n.d. | |
| 79 | 100.0 | 0.6 | 16660 | 74 | |
| 82 | 18.5 | n.d. | 1208 | n.d. | |
| 86 | 35.7 | n.d. | 4160 | n.d. | |
| 103 | 43.6 | n.d. | 3720 | n.d. | |
| 105 | 15.1 | n.d. | 1150 | n.d. | |
| 114 | 26.8 | n.d. | 1740 | n.d. | |
| 117 | 23.6 | n.d. | 3040 | n.d. | |
| 118 | 15.6 | n.d. | 1064 | n.d. | |
| 126 | 41.8 | n.d. | 4000 | n.d. | |
| 135 | 26.2 | n.d. | 1900 | n.d. | |
| 142 | 10.4 | n.d. | 680 | n.d. | |
| 143 | 7.8 | n.d. | 566 | n.d. | |
| 155 | 25.6 | n.d. | 2340 | n.d. | |
| 156 | 28.7 | n.d. | 2340 | n.d. | |
| 161 | 19.9 | n.d. | 2000 | n.d. | |
| 164 | 18.0 | n.d. | 1286 | n.d. | |
| 168 | 33.5 | n.d. | 6240 | n.d. | |
| 171 | 27.9 | n.d. | 2280 | n.d. | |
| 176 | 32.2 | n.d. | 3320 | n.d. | |
| 177 | 57.1 | n.d. | 8720 | n.d. | |
| 192 | 4.3 | n.d. | 186 | n.d. | |
| 204 | 49.0 | n.d. | 5460 | n.d. | |
| 208 | 35.7 | n.d. | 3240 | n.d. | |
| 209 | 25.7 | n.d. | 1580 | n.d. | |
| 212 | 11.8 | n.d. | 1100 | n.d. | |
| 220 | 4.5 | n.d. | 238 | n.d. | |
| KRAS G12C | 73 | 4.9 | n.d. | 278 | n.d. |
| 78 | 24.2 | n.d. | 2200 | n.d. | |
| 120 | 6.6 | n.d. | 858 | n.d. | |
| 123 | 15.8 | n.d. | 1528 | n.d. | |
| 149 | 4.2 | n.d. | 352 | n.d. | |
| 162 | 12.8 | n.d. | 1228 | n.d. | |
| 194 | 30.9 | n.d. | 2540 | n.d. | |
| 206 | 12.0 | n.d. | 882 | n.d. | |
| 215 | 32.4 | n.d. | 2560 | 4 | |
| PIK3CA E545K | 65 | 58.6 | 3.5 | 11260 | 43 |
| 184 | 31.2 | n.d. | 2660 | n.d. | |
| PIK3CA H1047R | 138 | 24.9 | n.d. | 1499 | n.d. |
n.d., not detected.